MBX Biosciences, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $53.42
- 52-Week Range
- $26.00 – $72.64
- Market Cap
- $2.65B
- P/E (TTM)
- —
- EPS (TTM)
- -3.03
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.61
- PEG Ratio
- —
- Return on Equity
- -33.72%
- Return on Assets
- -22.25%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 19.58
- Debt/Equity
- 0.01
- Total Debt
- $3.29M
- Free Cash Flow
- $-54.00M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $2.17B
Market Snapshot
About
MBX Biosciences, Inc. is a clinical-stage precision endocrinology company developing peptide-based therapeutics for endocrine and metabolic disorders. The company focuses on diseases caused by hormonal imbalances, including hypoparathyroidism, post-bariatric hypoglycemia, and growth hormone deficiency. Their approach targets specific receptors to restore normal physiological function.